AR032624A1 - Derivados de fenilamina ciclica, uso de los mismos para la fabricacion de medicamentos y composicion farmaceutica - Google Patents

Derivados de fenilamina ciclica, uso de los mismos para la fabricacion de medicamentos y composicion farmaceutica

Info

Publication number
AR032624A1
AR032624A1 ARP010103382A ARP010103382A AR032624A1 AR 032624 A1 AR032624 A1 AR 032624A1 AR P010103382 A ARP010103382 A AR P010103382A AR P010103382 A ARP010103382 A AR P010103382A AR 032624 A1 AR032624 A1 AR 032624A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
halogen
het
mono
Prior art date
Application number
ARP010103382A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR032624A1 publication Critical patent/AR032624A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Fodder In General (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Derivados de fenilamina cíclica, que comprenden un compuesto de la Formula (1) en la cual: A es Ar o Het; X es -OCH2-, -SCH2-, o un enlace; T1 es (CH2)m; T2 es (CH2)n; T es un enlace, alquilo C1-6 sustituido en forma opcional con R11, alquenilo C2-7 sustituido en forma opcional con R11, alquinilo C2-7, alquiltio C1-6, alquilamino C1-6, alcoxoalquilo C1-6 por grupo funcional alquilo, alquiltioalquilo C1-6 por grupo funcional alquilo, alcoxi C1-6, alcoxialquilo C1-6, alquiloxoalquilo C1-6 por grupo funcional alquilo, acilo C2-7, o alquenilcarbonilo C3-8; R1, R2 y R3 son, cada uno, en forma independiente, hidrogeno, alquilo C1-6, cicloalquilo C3-8, hidroxi, halogeno, trifluorometilo, alcoxi C1-6, benciloxi, aliloxi, propargiloxi, aciloxi C2-7, ciano, nitro, amino, aminocarbonilo, alquilamino C1-6, dialquilamino C1-6 por grupo alquilo, formamido, ureido, acilamino C2-7, alquilsulfoniloamino C1-6, arilsulfoniloamino, dialquiloxifosforilamino C1-6 por grupo alquilo, dihidroxifosforilamino, -CO2-alquilo C1-6, o Ar sustituido en forma opcional con R11; R4 es hidrogeno, alquilo C1-6, halogeno, hidroxi, alquiloxi C1-6, alquiltio C1-6, amino, alquilamino C1-6, carboxi, acilo C2-7, ArCO-, alcoxicarbonilo C2-7, aminocarbonilo, alquilaminocarbonilo C2-7, alquilsulfonilo C1-6, o alquilsulfonilamino C1-6; R5 se selecciona entre las formulas (2) a (12); Aa es (i) un amino ácido, en el cual el nitrogeno del amino ácido está aherido al carbonilo adyacente de R5; o (ii) un éster de alquilo de un amino ácido, en el cual el nitrogeno del amino ácido está adherido al carbonilo adyacente de R5, y el grupo funcional alquilo del éster de alquilo contiene C1-6;Y y Z son, cada uno, en forma independiente, NR7, O, o S; X1 y X2 son, cada uno, en forma independiente, CO o SO2; una línea de puntos representa un doble enlace opcional; R6, R7 y R8 son, cada uno, en forma independiente, hidrogeno, alquilo C1-6 sustituido o no por R11, R12 y R13; alquenilo C2-7 sustituido o no por R11, R12 y R13; alquinilo C2-7 sustituido o no por R11; cicloalquilo C3-8 sustituido o no por R11, R12 y R13; bicicloalquilo C7-11 sustituido o no por R11, R12 y R13; -CO2-alquilo C1-6; Het sustituido o no por R11, R12 y R13; o Ar sustituido o no por R11, R12 y R13; o cuando R6 y R7 están incluidos en un nitrogeno comun, pueden unirse para formar un heterociclo saturado de 5-7 elementos que está sustituido o no por R11; R9 y R10 son, cada uno, en forma independiente, alquilo sustituido o no por R11, R12 y R13; Ar es, en forma opcional, mono-, di-, o tri-sustituido por R15; Ar fusionado a un anillo de cicloalquilo C3-8, y, en forma opcional mono-, di-, o tri-sustituido por R15; o Het, en forma opcional, mono-, di-, o tri-sustituido por R15; R11, R12, o R13 son, cada uno, en forma independiente, alquilo C1-6, halogeno, alquenilo C2-7, alquinilo C2-7, cicloalquilo C3-8, Ar-alquilo C1-6, Ar sustituido o no por R14, Het sustituido o no por R14, hidroxi, alcoxi C1-6, Ar-oxi, oxo, -CN, -CHO, -CO2H, -OCO2-alquilo C1-6, -CO2-alquilo C1-6, -CO2-Ar-, -CO2-alquil C1-6-Ar, -OCO2-Ar, -CONH2, -CONHOH, amino, alquilamino C1-6, dialquilamino C1-6, -NHCONH-alquilo C1-6, -NHSO2-alquilo C1-6, -NHSO2-Ar, o -NHSO2-Het; o cuando R11 y R12 están incluidos en un átomo de carbono comun de un grupo funcional alquilo, pueden unirse para formar un anillo espiro cicloalquilo C3-8; R14 es halogeno, alcoxi C1-6, alquilo C1-6, alquenilo C2-7, alquinilo C2-7, hidroxi, acilo C2-7, -SO2-alquilo C1-6, -CO2-alquilo C1-6, o alcoxicarbonilalquilo C3-13; R15 es (a) hidroxi, halogeno, -CN, -NR16R16, -OR16, -SR16, trifluorometilo, alquilo C1-6, -SO2R17, -O-alquil C1-6-CO2R17, -CO2R17, -OCOR17, -NR16COR17, -COR17, -NR16SO2R17, o -NR16CO2R16; o (b) alquilo C1-6 mono- o di-sustituido con hidroxi, halogeno, -CN, -NR16NR16, -OR16, -SR16, trifluorometilo, alquilo C1-6, -SO2R17, -CO2R17, -OCOR17, -NR16COR17, -COR17, -NR16SO2R17, -NR16CO2R16, Ar que puede en ser o no, mono- o di-sustituido por R16, -OR16, -NR16R16, o halogeno, o Het que puede ser o no, mono- o di-sustituido por R16, -OR16, -NR16R16, o halogeno; (c) Het que puede ser o no, mono- o di-sustituido por R16, -OR16, -NR16R16, o halogeno; o (d) Ar que puede ser o no, mono- o di-sustituido por R16, -OR16, -NR16R16, o halogeno; R16 es hidrogeno, alquilo C1-6, cicloalquilalquilo C4-14, bencilo, Ar o Het, en los cuales los grupos funcionales Ar o Het pueden ser, en forma opcional, mono-, di-, o tri-sustituidos con halogeno, nitro, alquilamino C1-6, dialquilamino C1-6, trifluorometilo, alquilo C1-6, alcoxi C1-6, alquiltio C1-6, -CO2H, -CO2alquilo C1-6, o -SO2alquilo C1-6; R17 es R16 o -NR16R16; Het es un heterociclo monocíclico o bicíclico de 5-10 átomos en el anillo, que tiene 1-4 heteroátomos seleccionados de oxígeno, nitrogeno, y azufre; en el cual el heterociclo puede ser saturado, insaturado o parcialmente saturado; y puede estar, en forma opcional fusionado a un anillo de fenilo; Ar es un sistema aromático que contiene 1-2 anillos aromáticos carbocíclicos C6-10; m = 1-3; y n = 1-3; o una de sus sales aceptables para uso farmacéutico; el uso de dichos derivados para la fabricacion de un medicamento para uso farmacéutico, que son utiles en el tratamiento o la inhibicion de trastornos metabolicos relacionados con la resistencia a la insulina o la hiperglucemia (asociados normalmente con la obesidad o intolerancia a la glucosa), ateroesclerosis, trastornos gastrointestinales, inflamacion neurogenética, glaucoma, hipertension ocular y necesidad frecuente de orinar; y son de particular utilidad en el tratamiento o la inhibicion de la diabetes tipo II y composiciones farmacéuticas que los comprenden.
ARP010103382A 2000-07-17 2001-07-16 Derivados de fenilamina ciclica, uso de los mismos para la fabricacion de medicamentos y composicion farmaceutica AR032624A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21862700P 2000-07-17 2000-07-17

Publications (1)

Publication Number Publication Date
AR032624A1 true AR032624A1 (es) 2003-11-19

Family

ID=22815833

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103382A AR032624A1 (es) 2000-07-17 2001-07-16 Derivados de fenilamina ciclica, uso de los mismos para la fabricacion de medicamentos y composicion farmaceutica

Country Status (10)

Country Link
US (2) US6525202B2 (es)
EP (1) EP1301482A1 (es)
JP (1) JP2004504299A (es)
CN (1) CN1455771A (es)
AR (1) AR032624A1 (es)
AU (1) AU2002222930A1 (es)
BR (1) BR0112522A (es)
CA (1) CA2416245A1 (es)
MX (1) MXPA03000518A (es)
WO (1) WO2002006232A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2525801A (en) * 1999-12-17 2001-06-25 Sanofi-Synthelabo Phenoxypropanolamines, method for producing them and pharmaceutical compositionscontaining them
US6410734B1 (en) * 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6498170B2 (en) 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US7071220B2 (en) * 2000-09-18 2006-07-04 Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivatives
US6909515B2 (en) 2001-01-22 2005-06-21 Cyberoptics Corporation Multiple source alignment sensor with improved optics
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
BE1014245A4 (fr) * 2001-04-03 2003-07-01 Malak Jean Composes chimiques derives de l'octopamine et leurs utilisations en tant qu'agonistes beta 3-adrenergiques.
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US7521465B2 (en) * 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
CA2514573A1 (en) 2003-01-27 2004-08-12 Astellas Pharma Inc. Thiazole derivatives and their use as vap-1 inhibitors
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1479677A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
WO2004108674A1 (ja) * 2003-06-05 2004-12-16 Kissei Pharmaceutical Co., Ltd. アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途
DE10351271A1 (de) * 2003-10-31 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
JPWO2006016637A1 (ja) * 2004-08-11 2008-05-01 杏林製薬株式会社 新規環状アミノ安息香酸誘導体
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
EP1862464A4 (en) * 2005-03-23 2010-08-25 Kyorin Seiyaku Kk NEW CYCLIC AMINOPHENYL ALKANIC ACID DERIVATIVE
BRPI0617364A2 (pt) 2005-10-13 2011-07-26 Orchid Res Lab Ltd compostos heterocÍclicos como inibidores de pstat3/il-6
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
MY155320A (en) * 2007-10-05 2015-09-30 Acucela Inc Alkoxy compounds for disease treatment
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
NZ588807A (en) 2008-05-05 2011-07-29 Sanofi Aventis Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
EP2427194B1 (en) * 2009-05-08 2014-10-08 Merck Sharp & Dohme Corp. Pyrrolidine-derived beta 3 adrenergic receptor agonists
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
CN103269692B (zh) 2010-08-03 2018-02-23 韦利塞普特治疗有限公司 用于治疗膀胱过度活动症的β‑3肾上腺素能受体激动剂和毒蕈碱性受体拮抗剂的药物组合
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US8546443B2 (en) 2010-12-21 2013-10-01 Boehringer Ingelheim International Gmbh Benzylic oxindole pyrimidines
WO2013062881A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
EP2771006B1 (en) 2011-10-27 2016-05-25 Merck Sharp & Dohme Corp. Process for making beta 3 angonists and intermediates
WO2014150639A1 (en) 2013-03-15 2014-09-25 Merck Sharp & Dohme Corp. Process for preparing beta 3 agonists and intermediates
CN107205964A (zh) 2014-12-03 2017-09-26 威力塞帕特治疗股份有限公司 使用调节释放索拉贝隆用于下尿路症状的组合物和方法
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
CN107215770A (zh) * 2017-06-27 2017-09-29 中国煤炭科工集团太原研究院有限公司 矿用液压绞车的多自由度钩头
KR20220130127A (ko) * 2019-12-19 2022-09-26 카스마 테라퓨틱스, 인코포레이티드 Trpml 조절제
EP4404924A1 (en) * 2021-09-23 2024-07-31 Curasen Therapeutics, Inc. Beta adrenergic agonist and methods of using the same

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348393A (en) 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
EP0089154A3 (en) 1982-03-12 1984-08-08 Beecham Group Plc Ethanolamine derivatives, their preparation and use in pharmaceutical compositions
GB2163150B (en) 1984-07-19 1988-05-25 Sandoz Ltd 3-aminopropoxyaryl derivatives
GB8528633D0 (en) 1985-11-21 1985-12-24 Beecham Group Plc Compounds
US4813998A (en) 1986-02-27 1989-03-21 Janssen Pharmaceutica N.V. Herbicidal 1H-imidazole-5-carboxylic acid derivatives
US5143928A (en) 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
EP0449261A3 (en) 1990-03-29 1992-02-26 Kabushiki Kaisha Toshiba Resin composition for an optical disc and an optical disc using it
DE4117904A1 (de) * 1991-05-31 1992-12-03 Basf Ag Substituierte n-phenylpiperidine
ZA936324B (en) 1992-08-31 1994-03-22 Sankyo Co Oxazolidine derivatives having anti-diabetic and anti-obesity properties their preparation and their therapeutic uses
US5998452A (en) 1993-06-23 1999-12-07 Chugai Seiyaku Kabushiki Kaisha Benzene derivatives, compositions and methods for treating ischemic diseases
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
CA2145257A1 (en) 1994-03-23 1995-09-24 Takashi Fujita Thiazolidine and oxazolidine derivatives, their preparation and their medical use
US5561142A (en) 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5789402A (en) 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
US5614523A (en) 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5741789A (en) 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
ATE239694T1 (de) * 1995-10-26 2003-05-15 Mitsubishi Pharma Corp Phenylethanolamin-verbindungen und ihre anwendung als beta3 agonisten, verfahren zu ihrer herstellung und zwischenprodukte ihrer herstellung
EP0801060A1 (en) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
AU712057B2 (en) 1996-06-07 1999-10-28 Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity
AU2995497A (en) 1996-07-26 1997-11-19 Dr. Reddy's Research Foundation Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
EP0827746B1 (en) 1996-09-05 2002-04-03 Eli Lilly And Company Carbazole analogues as selective beta3 adrenergic agonists
WO1998022480A1 (en) 1996-11-18 1998-05-28 Smithkline Beecham Plc Phosphorus containing aryloxy or arylthio propanolamine derivatives
BR9807096A (pt) 1997-01-28 2000-04-18 Merck & Co Inc Composto, processos para o tratamento do diabetes, da obesidade em um mamìfero, para reduzir nìveis de triglicerìdeos e nìveis de colesterol ou elevar nìveis de lipoproteìnas de alta densidade, para diminuir a motilidade do intestino, para reduzir inflamação neurogênica das vias aéreas e a depressão e para tratar distúrbios gastrintestinais, e, composições para o tratamento dos distúrbios acima e farmacêutica
US6150378A (en) 1997-10-07 2000-11-21 Cephalon, Inc. Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors
US6346532B1 (en) 1997-10-17 2002-02-12 Yamanouchi Pharmaceutical Co., Ltd. Amide derivatives or salts thereof
FR2780057B1 (fr) 1998-06-18 2002-09-13 Sanofi Sa Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
US6214842B1 (en) 1999-05-12 2001-04-10 Michael S. Malamas Amino-thiazolidinediones useful in the treatment of insulin resistance and hyperglycemia
FR2798126B1 (fr) 1999-09-08 2001-10-19 Sanofi Synthelabo Heteroaryloxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2802533B1 (fr) 1999-12-17 2002-02-15 Sanofi Synthelabo Phenoxypropanolamines, leur preparation et leur application en therapeutique
AU2525801A (en) * 1999-12-17 2001-06-25 Sanofi-Synthelabo Phenoxypropanolamines, method for producing them and pharmaceutical compositionscontaining them
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6509358B2 (en) 2000-07-17 2003-01-21 Wyeth Piperidino-phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6498170B2 (en) 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US6410734B1 (en) 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6514991B2 (en) 2000-07-17 2003-02-04 Wyeth Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists
US6444685B1 (en) * 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
US6395762B1 (en) 2000-07-17 2002-05-28 American Home Products Corporation Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6458817B1 (en) 2000-07-17 2002-10-01 Wyeth Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists

Also Published As

Publication number Publication date
US20020028835A1 (en) 2002-03-07
CA2416245A1 (en) 2002-01-24
US6525202B2 (en) 2003-02-25
AU2002222930A1 (en) 2002-01-30
WO2002006232A1 (en) 2002-01-24
EP1301482A1 (en) 2003-04-16
CN1455771A (zh) 2003-11-12
US7022716B2 (en) 2006-04-04
BR0112522A (pt) 2003-06-24
JP2004504299A (ja) 2004-02-12
MXPA03000518A (es) 2003-05-14
US20030144326A1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
AR032624A1 (es) Derivados de fenilamina ciclica, uso de los mismos para la fabricacion de medicamentos y composicion farmaceutica
AR058885A1 (es) Compuestos de piperidina 3,5-sustituidos
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR043038A1 (es) Compuestos de pirazolotriazina y usos de los mismos
AR049711A1 (es) Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
AR051294A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
PE20040655A1 (es) Nuevos derivados de glicosido de tiofeno, procedimientos para su preparacion y medicamentos que los contienen
AR068045A1 (es) Derivados de catecolamina y prodrogas de los mismos
AR043111A1 (es) Derivados monoacilados de o-fenilendiaminas
AR059428A1 (es) Pirazoles para el tratamiento de enfermedades mediadas por la modulacion de los receptores de histamina h3 y una composicion farmaceutica que los comprende.
AR075050A1 (es) Dicianopiridinas alquilamino-sustituidas
AR020551A2 (es) Compuestos macrolidos, composiciones y su uso para la preparacion de medicamentos.
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
AR078152A1 (es) Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden
AR044045A1 (es) Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion
AR029811A1 (es) Un procedimiento para la preparacion de una sal de citalopram, base cristalina de citalopram obtenida por dicho procedimiento y una composicion farmaceutica
AR066460A2 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
AR079236A1 (es) Derivados de ciclohexano y usos de los mismos
AR049398A1 (es) Derivados de sulfamato y sulfamida; una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento util para el tratamiento de la epilepsia y trastornos relacionados.
AR053092A1 (es) Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis
AR050261A2 (es) Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento
PE20060273A1 (es) Derivados de tetrahidroisoquinolilsulfonamidas como moduladores del receptor h3
AR057906A1 (es) Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta.
PE20081782A1 (es) Agonistas de adrenoreceptores alfa2c

Legal Events

Date Code Title Description
FB Suspension of granting procedure